Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	15.80B +9.6%
Revenue (ttm)	6.11B +13.6%
Net Income	769.95M +7.2%
EPS	1.58 +1.8%
Shares Out	501.47M
PE Ratio	19.95
Forward PE	n/a
Dividend	0.55 (1.76%)
Ex-Dividend Date	Jul 11, 2025

Volume	629,926
Average Volume	983,814
Open	31.30
Previous Close	31.00
Day's Range	31.25 - 31.60
52-Week Range	26.28 - 39.80
Beta	-0.05
RSI	38.67
Earnings Date	Mar 30, 2026

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2024, Synmosa Biopharma's revenue was 5.55 billion, an increase of 7.96% compared to the previous year's 5.14 billion. Earnings were 684.68 million, an increase of 15.11%.